Castle Biosciences Corp (CSTL) - צמיחה צפויה ברווח למניה לשנה הבאה

Castle Biosciences (CSTL) leverages unique DecisionDx patents to create a powerful defensive moat, which illustrates the trend of earnings per share growth forecasts, where 27.00 forms the current metric value. The business relies on a dermato-oncology molecular ecosystem characterized by high switching costs. Stability is provided by specialized US laboratories whose high-precision tests are integrated into clinical skin cancer diagnostic standards.

For Castle Biosciences (CSTL), a developer of AI-driven skin cancer diagnostics, the consensus forward EPS growth rate reflects market expectations for the scaling of genomic tests. This metric is calculated as the percentage change in expected earnings per share over the next four quarters, allowing investors to assess the monetization potential of innovations and the overall resilience of the company's business model.